Menu
Non-invasive, AI-enabled product helps CT readers to accurately*, efficiently, and consistently identify narrowings in the coronary arteries, advancing the HeartFlow portfolio
MOUNTAIN VIEW, Calif. – April 17, 2023 — HeartFlow, Inc. today announced the launch of the RoadMap analysis, a new AI-enabled product that assists CT readers to accurately*, efficiently, and consistently identify stenoses in the coronary arteries. With its expanded product portfolio, HeartFlow is now the only company to offer anatomical and physiological visualization of the coronary arteries to help improve heart disease diagnosis and enable physicians to guide treatment decisions.
Heart disease is the leading cause of death in the United States.1 Despite advancements in the diagnosis and treatment of coronary artery disease (CAD), the most common heart disease, the complexities of symptoms and the limitations of traditional testing can make it challenging for physicians to correctly identify the condition.
The RoadMap analysis is designed to help improve CAD diagnosis by providing CT readers with a 2D visual that shows the location and severity of anatomic narrowings in the coronary arteries. It has been shown to provide accurate*, reproducible results and helps facilitate standardized and high-quality CT interpretation.2 The RoadMap analysis, alongside HeartFlow’s FFRCT, aligns with the recently updated AHA/ACC chest pain guidelines and enhances existing diagnostic workflows by guiding treatment decisions and improving patient outcomes.3
“As a leader in non-invasive diagnosis of CAD, HeartFlow is intimately familiar with the challenges associated with diagnosing heart disease,” said John Farquhar, Chief Executive Officer of HeartFlow. “The RoadMap analysis underscores our commitment to delivering products that meet the needs of physicians and ultimately helps deliver improved treatment plans for patients with suspected CAD – no matter how their disease may present itself.”
“The RoadMap analysis has already been a valuable tool for our organization in helping us better pinpoint areas of stenosis and its severity,” said Michael Morris, M.D., a Diagnostic Radiology Specialist at Banner Health. “It helps our providers confidently determine the best next steps necessary to achieve improved patient care and outcomes.”
The HeartFlow product suite now enables physicians to gain a more comprehensive understanding of a person’s CAD by assessing the coronary artery anatomy (RoadMap analysis), physiology (HeartFlow® FFRCT), and plaque information (Plaque analysis) based on coronary computed tomography angiography (CCTA). When combined, they offer the most accurate approach to predicting the risk of a heart attack.4
HeartFlow is the global leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced AI technology. Headquartered in Mountain View, California, our technology has been published in more than 500 peer-reviewed publications that showcase the value of anatomy, physiology, and plaque. We began our journey to improve coronary artery disease (CAD) diagnosis with FFRCT and have now expanded our product portfolio to include anatomic stenosis and plaque information. To date, clinicians have used our technology for over 180,000 patients to aid in the diagnosis of heart disease. For more information, visit www.heartflow.com and connect onTwitter and LinkedIn.
Linly Ku
HeartFlow
media@heartflow.com
* Accuracy data compared to measured QCA angiogram data. Data on file.
The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.
© 2023 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.